Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.
Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...
I can’t hear it because my trophies, they kind of, like, echo around me,” Logano quipped during a Zoom call with media Wednesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback